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quality, prospective outcomes research. The methods for
establishing a network of pharmacies, recruiting patients,
and obtaining patient informed consent will be described.
The procedures for developing telephone questionnaires
and for collecting data on a broad range of topics, such as
patient demographics, drug utilization and compliance,
prescribing patterns, health services utilization, adverse
events, quality of life, out-of-pocket expenditures and
productivity losses will be discussed. Finally, the applica-
tions of community pharmacy-based outcomes research
studies will be presented. These include pharmacoeco-
nomic evaluations for formulary registration, drug utili-
zation review for improving therapeutic regimens, devel-
oping disease management strategies for optimizing care,
patient profiling for investigating utilization and compli-
ance patterns and measuring health outcomes to assess
the impact of health policy decisions. This workshop will
benefit industrial and academic researchers engaged in
prospective pharmacoeconomic assessments, health ser-
vices evaluations and outcomes research. Individuals in-
terested in outcomes research methodology and the rela-
tionship between outcomes research and health policy
decision-making may also benefit from attending.
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The growth in the number of studies analyzing healthcare
costs has been exponential. However, recently published
data cast doubt about their applicability. We hypothesize
that this situation may be, in part, due to the lack of
timely, validated, standardized databases. Additionally,
many of the rigorous procedures developed to assure ve-
racity of clinical research data have not been consistently
applied to the conduct of outcomes research. Similarly,
doubts about the accuracy and timeliness of administra-
tive information may hinder its application to the pro-
cesses of clinical research. We suggest that through care-
ful construction of a clinical financial database and
judicious application of clinical research tools and prac-
tices, some of these barriers may be overcome.
This workshop aims to:
1) Describe the Perspective Comparative Database
(PCD), Premier, Inc.'s standardized nationwide
ISO-center clinical financial dataset through:
• review of the methodology by which standard
data elements are defined, normalized, mapped
and validated;
• review of the methodology by which stan-
dardized costs are validated.
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2) Describe PCD's efficacy in the research arena:
• provide examples of clinical outcomes im-
provement;
• provide examples of application to clinical re-
search in the arena of patient identification and
protocol development;
• provide examples of combination with clini-
cal research tools in performance of pharmaco-
economic studies.
3) Suggest methods by which a combined PCD/clini-
cal information database might allow for rapid ac-
quisition and analysis of pharmacoeconomic data.
This workshop is intended for industry professionals
and non-industry researchers involved in applied phar-
macoeconomics, decision support systems, and clinical
research.
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Although clinical guidelines have been gaming wide-
spread acceptance as a management tool, practical diffi-
culties in implementation and measurement of outcomes
have been obstacles in their widespread use. Their com-
plexity may discourage consistent use in everyday prac-
tice, while the lack of data tracking their implementation
has limited the assessment of outcomes. Disease State
Management Tracker (DSMT) addresses these concerns
with a system that makes it easy for the practitioner to
enter patient assessments and track services received, as
well as monitor patient progress and outcomes. DSMT is
based on the components of disease state management,
namely: treatment algorithms, clinical decision making,
and outcomes reporting.
Complex treatment algorithms are easily stored and
analyzed using either retrospective or prospective data.
The DSMT software was developed as an application for
the Windows 9S/NT environment. The workshop will be
presented in the form of an overview of the DSMT and its
functionalities while using community acquired pneumo-
nia as an example disease state. The attendee will be able
to convert locally or nationally developed clinical path-
ways and enter them into the DSMT. Next, patient as-
sessment, assignment into management cells for provision
of services, and determination of patient outcomes in the
DSMT will be reviewed. Finally the capability of DSMT
to generate extensive reports will be demonstrated. Some
standard reports include determination of cost of treat-
ment via the clinical pathway as well as cost of deviations
from the pathway. DSMT is being used for various dis-
ease states including community acquired pneumonia,
asthma, osteo-arthritis, osteoporosis as well as in several
